ABSTRACT. Familial Mediterranean fever is a recessive autoinflammatory disease that is frequent in Armenians, Jews, Arabs, and Turks. The MEFV gene is responsible for this disease. We looked for MEFV gene variations (polymorphism and mutations) in a population that resides in Central Anatolia, Turkey. DNA was extracted from peripheral blood leukocytes of 802 familial Mediterranean fever patients. The DNA sequence data were examined for approximately 150 different mutations and polymorphisms, including single nucleotide polymorphisms in different exons of the MEFV gene. The male:female ratio of these patients was 1.44:1. Mutations were detected in 48.1% of the patients; 7.5% were homozygous, 11.1% were compound heterozygous and 31.5% had only one identifiable mutant allele. No mutations were detected in 51.9% of the patients. The main clinical characteristics of the patients were: abdominal pain in 20.6%, arthritis in 22.9%
INTRODUCTION
Familial Mediterranean fever (FMF: OMIM #249100) is an autosomal recessive disorder characterized by recurrent attacks of pleuritis, febrile peritonitis and synovitis. It affects mainly Turks, Arabs, Armenians, and non-Ashkenazi Jews (Medlej-Hashim et al, 2010) . A familial Mediterranean fever (MEFV) gene has been identified on the short arm of chromosome 16 and several mutations in this gene have been demonstrated in FMF patients (Consortium TFF, 1997; Consortium TIF, 1997) . The MEFV gene consists of 10 exons and encodes a 781-amino acid protein called pyrin, which is expressed in polymorphonuclear cells, cytokine-activated monocytes, dendritic cells, and synovial fibroblasts (Centola et al., 2000; Diaz et al., 2004) . Because of the restricted expression of pyrin in innate immune cells, the major role of pyrin appears to be the regulation of inflammation (Kastner, 2005) . Mutations interfere with the pyrin domain, allowing an uninterrupted inflammatory cascade. To date more than 150 mutation gene alterations located in the MEFV gene have been identified (Öztürk et al., 2008) . Five founding mutations M694V, V726A, M680I, M694I (in exon 10), and E148Q (in exon 2) are the most common MEFV mutations (Sarrauste De Menthière C, 2003; Milhavet et al., 2008) . Several reports have shown that the M964V mutation is associated with severe disease featuring early onset, high frequency of attacks, the need for the high doses of colchicine and high frequency of amyloidosis in untreated patients (Saatçi et al., 1997; Mattitt et al., 2006; Düşünsel et al., 2008; Paşa et al., 2008; Jarjour, 2010) . The syndrome also features high levels of erythrocyte sedimentation rate, C-reactive protein and serum amyloid A, but case-specific consensus on phenotype and genotype in FMF patients has not been reached (Aldea et al., 2004) . The carrier frequency of MEFV mutations is quite high in the 4 classically affec-
The carrier frequency of MEFV mutations is quite high in the 4 classically affected populations, ranging from 37 to 39% in Armenians and Iraqi Jews to 20% in Turks, North African and Ashkenazi Jews and Arabs (Pras and Kastner, 1997; Shinar et al., 2000; Schouten et al., 2002 , van Gijn et al., 2008 .
All molecular genetic methods for detecting mutations are based on differences in the DNA sequence. Logically, DNA sequencing would appear to be the best approach to determining the mutations. DNA sequencing was originally performed by using radioactive labels for the detection of the reaction products, an approach that is unsuitable for clinical use. Current DNA sequencing protocols use fluorescent nucleotides to label the DNA. The sequence is then read with an automated instrument. DNA sequencing generally begins with polymerase chain reaction (PCR) amplification of DNA regions of interest, followed by sequencing reactions with the PCR products. Instruments that perform automated analysis of DNA sequencing gels are based on real-time detection of fluorescence-labeled sequencing reaction products (Olive and Bean, 1999) . In this study, we examined the entire MEFV coding sequence of symptomatic FMF patients to look for mutations potentially missed by currently used screening methods. This study is the first to perform DNA sequence analysis on the whole MEFV coding sequence in all subjects.
PATIENTS AND METHODS

Patients
A total of 802 patients came to our laboratory because of FMF symptoms -especially abdominal, renal and arthralgia symptoms -between June 2008 and December 2010. They were referred from various clinics with specialties in rheumatology, urology, nephrology, and gastroenterology, among others. The mean age of the patients was 30.7 years. Written consent was obtained from all participants, and the review board at our institution approved the study.
Diagnostic techniques
We drew 5 mL blood from each patient into tubes containing ethylenediaminetetraacetic acid. DNA was extracted using a commercial kit (QIAamp DNA mini kit; Qiagen, Hilden, Germany). Sequencing was performed using a 48-well capillary machine (MegaBACE, Amersham) for the analysis of the whole MEFV coding sequence. All MEFV gene exons were screened for causative mutations via direct DNA sequencing so as not to miss any mutations. We have applied this technique to approximately 150 different mutations and polymorphisms including single-nucleotide polymorphisms in different exons of the MEFV gene. The sequencing data were analyzed using Sequencher 4.6 (Gene Codes, Ann Arbor, MI, USA). All nucleotide alterations were distinguished using this method.
RESULTS
The study included 802 patients with a male:female ratio of 1.44:1 (473 females, 329 males; mean age, 25.0 ± 11.25 years; range, 5-70 years). Mutations were detected in 386 (48.1%) patients; 53 (7.5%) were homozygous, 87 (11.1%) were compound heterozygous, and 246 (31.5%) had only one identifiable mutant allele. No mutations were detected in 416 (51.9%) patients (Table 1 ). The age of the male patients ranged from 5 to 75 years. The mean age was 31 years. The age of the female patients ranged from 3 to 72 years. The mean age was 29 years. The mean ages of the patients with and without FMF mutations regardless of gender were 30 and 31 years, respectively. The mean age of patients with MEFV gene mutations was 30 years.
The main clinical characteristics of the patients were as follows: abdominal pain in 20.6%, arthritis in 22.9%, and amyloidosis in 4.6%. Sixty-six percent of patients had a positive family history of FMF. The presence of parental consanguinity was also deter-mined for all patients, and it occurred in 19.4% of patients. MEFV mutations were studied using a whole MEFV gene sequencing method. No mutations were detected in 416 patients (51.9%; Table 2 ). Results in 802 FMF patients revealed that M694V was the most frequent mutation (28%), followed by V726A (11.7%), E148Q (9.1%), and M680I(G/C) (3.9%) in the Central Anatolian population (Figure 1 ). The rarest mutations were heterozygous forms of F479L (in exon 5), M694I (in exon 10), E225D, E230K, T267I (all three in exon 2), I591T (in exon 9), and combined heterozygous forms of E148Q/V726A, E148Q/M694I, E167D/M694V, E167D/F479L (E167D is in exon 2), M694V/K695R, M694V/F479L, M694V/M694I, M694I/V726A, and M694V/P369S. The frequency of the rare mutations was 0.03% (only one patient had all of these mutations). Most of the rare mutations were heterozygous. Four common mutations (M694V, E148Q, M680I(G/C), and V726A) were found in 52.7% of patients (Figure 2 ). The study population had a high rate of carriers.
Mutation
Number of patients with different FMF symptoms (N)
Allele 1  Allele 2  Abdominal pain  Arthritis  Amyloidosis   M694V  V726A  8  8  6  M694V  M694V  13  13  7  V726A  V726A  2  --E148Q  E148Q  4  1  -A744S  -7  8  -V726A  -23  15  7  M694V  -49  54 Table 2 . Genotypes and frequency of detected mutations in Turkish population.
Figure 1. Chromatogram of a patient with M680I(G/C) heterozygosity (arrow).
In addition to 7 synonymous polymorphisms in exon 2 (D102D, G138G, and A165A), exon 3 (R314R), and exon 5 (E474E, Q476Q, and D510D), we found a T267I mutation in one heterozygous patient, E225D in one heterozygous patient, E230K in one heterozygous patient, I259V in one heterozygous patient, I591T in one heterozygous patient, F479L in one heterozygous patient, and M694I in one heterozygous patient. These additional mutations were found in different patients and these patients were severe cases of FMF (Table 3) . These mutations are nucleotide variations located in exons 2, 5, 9, and 10 that are not explored with denaturing gradient gel electrophoresis or reverse dot methods.
DISCUSSION
The identification of the MEFV gene and its various mutations provides a rational basis for medical and genetic counseling for the clinical treatment of FMF patients and their families. The prevalence of this disease in Turkey is approximately 0.1%, but it is estimated that the prevalence may be higher because many patients remain undiagnosed, particularly if they have mild forms of the disease. Furthermore, in Turkey, especially central Anatolia, in which consanguinity is widespread, the incidence of FMF may be higher than that observed. Ankara is situated in the center of Anatolia and receives migration from Central Anatolia, East Anatolia, and the Black Sea region. It is also a referral center for patients from those regions, and our laboratory is one of the main referral institutions. Therefore, the results of our study are representative of the populations living in those regions of Turkey. Most studies of FMF have reported that the disease affects both genders in a similar ratio (Saatçi et al., 1997; Milhavet et al., 2008) . MEFV gene mutations were similar in male and female FMF patients in our study. Likewise, clinical characteristics were generally comparable between males and females, although some features, such as abdominal pain or arthritis, occasionally differ.
MEFV gene mutations vary according to population characteristics such as familial history, parental consanguinity, migration, population type, and the presence of heterozygous carriers. Both the types and the frequency of mutation in such populations should be examined to protect the health of future generations (Marek-Yagel et al., 2009) .
In addition to clinical criteria, molecular studies for detecting disease-causing mutations are needed to confirm the diagnosis of FMF. Sequence analysis is quite precious in FMF diagnoses. We suggest this reliable and safe method for diagnosis in large FMF patient groups. The analysis of the whole MEFV gene has shown that M694V is the most frequent mutation in the population from Central Anatolia. Analysis of all mutations in the MEFV gene confirmed the diagnosis of FMF in 48.1% of these patients. The most common mutations were M694V, V726A, E148Q, and M680I(G/C). M694V was the most frequent mutation in patients with abdominal pain and arthritis in our study. Interestingly, M694V homozygosity and V726A heterozygosity were found more frequently in amyloidosis patients. The allele frequency of the M694V mutation was 0.0142, and a total of 195 (24.3%) patients had this mutation. M694V homozygotes accounted for 4.1% of the patients, 13.5% were M694V heterozygotes, and 17.6% were M694V compound heterozygotes. In previous studies, M694V was detected in 69-80% of FMF patients with arthritis and abdominal pain (Ince et al., 2002; Olgun et al., 2005) . The M694V mutation is the most prevalent mutation in Arabs (Mattit et al., 2006; Jarjour, 2010) , Lebanese, and Jordanians (Medlej-Hashim et al., 2000, 2005) , Turks (Yalçınkaya et al., 2000; Güneşaçar et al., 2005) , Armenians (Cazeneuve et al., 1999) , Iranian Azeri Turks (Esmaeili et al., 2008) , and Jews (Dewalle, 1998; Touitou, 2001 ). An association between homozygosity for the M694V mutation and arthritis in FMF patients has been reported by others (Brik et al., 1999; Kone et al., 2000; Olgun et al., 2005) . The clinical presentation of arthritis in FMF has variable forms. The M694V mutation is most likely associated with arthritis, one of the severe complications of FMF. All arthritis patients in Central Anatolia should be evaluated for FMF to prevent the development of chronic arthritis, abdominal pain, and amyloidosis. Data on genotype-phenotype correlation in FMF generally agree with the presence of M694V homozygosity and its correlation with the most severe FMF phenotypes and amyloidosis (Dewalle et al., 1998; Cazeneuve et al., 1999; Kone et al., 2000; Olgun et al., 2005; Jarjour, 2010; Jarjour and Dodaki, 2011) .
The most serious complication in FMF patients is chronic renal failure, which is highly associated with point mutations in the MEFV gene. The population in our study had a high rate of carriers, and V726A had the second-highest mutation frequency when our results were compared with those of other regions of Turkey and other Mediterranean groups (Shinar et al., 2000) . Therefore, we expect that the M694V mutation, which causes the worst pathologic phenotype, must be the mutation with the least penetration in patients with FMF (Marek-Yagel et al., 2009; Jarjour and Dodaki, 2011) . According to our study, chronic renal failure patients in the Central Anatolian population have a high rate of MEFV homozygous (M694V) and heterozygous (V726A) gene mutations.
In conclusion, MEFV gene mutations vary according to population characteristics such as familial history, parental consanguinity, migration, the presence of heterozygous carriers, and intrapopulation differentiation. Populations similar to the one in our study should be examined for mutation types and frequency to protect the health of future generations. Our study shows that the genetics of FMF are more complex than previously been appreciated and supports the mounting evidence that a single MEFV mutation may be associated with mild FMF symptoms. However, heterozygous patients presenting severe phenotypes should be further analyzed for less common second MEFV mutations using gene sequencing. In addition, our results have important implications for genetic counseling. We believe that this study will be helpful to clinicians by indicating the most frequently encountered FMF mutations in the Turkish population. Despite the current body of knowledge about FMF, prospective clinical studies with large numbers of patients across various ethnic groups will help to clarify this considerably debilitating disease.
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